Last reviewed · How we verify
NCT05224037: OGIG-01-22-LF
Comparative Efficacy of Liver Fibrosis and Steatosis Assessment With Fibroscan and iLivTouch
NA trial testing iLivTouch in Chronic Liver Disease in 100 participants. Completed in 31 December 2022.
15 March 2022
Quick facts
| Lead sponsor | Federal State Budgetary Scientific Institution "Federal Research Centre of Nutrition, Biotechnology |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 100 |
| Start date | 21 January 2022 |
| Primary completion | 15 March 2022 |
| Estimated completion | 31 December 2022 |
| Sites | 1 location across Russia |
Drugs / interventions tested
- iLivTouch
Conditions studied
- Chronic Liver Disease — all drugs for Chronic Liver Disease →
- Liver Fibrosis — all drugs for Liver Fibrosis →
- Liver Steatoses — all drugs for Liver Steatoses →
Sponsor
Federal State Budgetary Scientific Institution "Federal Research Centre of Nutrition, Biotechnology
Who can join
Adults 18 to 80, any sex, with Chronic Liver Disease or Liver Fibrosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is aimed to compare the results and operating characteristics of liver stiffness measurement with the use of Fibroscan (EchoSens, France) and iLivTouch (Wuxi Hisky Medical Technologies Co., China) in patients with chronic liver diseases.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
Verify or expand the search:
- PubMed search for NCT05224037
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Chronic Liver Disease
Currently open trials in the same condition.
- NCT06592820 — Endoscopic Ultrasound Shear Wave Elastography Study · recruiting
- NCT06318949 — Albumin Modifications as Early Biomarkers of Chronic Liver Diseases · NA · recruiting
- NCT06743464 — Effect of Perioperative Oral Rifaximin on Early Graft Dysfunction in Adult Living Donor Liver Transplant · NA · recruiting
- NCT06587568 — Mobile Chat Messaging for Alcohol Reduction in Patients With Chronic Liver Diseases · NA · active not recruiting
- NCT06493799 — In Patients With Chronic Liver Diseases(Alcoholic Liver Disease and Non-Alcoholic Fatty Liver Disease), LAENNEC(Human Pl · Phase 3 · recruiting
Other Federal State Budgetary Scientific Institution "Federal Research Centre of Nutrition, Biotechnology trials
Trials by the same sponsor.
- NCT06727279 — Assessment of Tolerability of Specialized Food Products Made Out of Vegetable Protein and Their Influence on Lipid Profi · NA · not yet recruiting
- NCT07121803 — The Influence of Specialized Food Products Based on Ice-Cream on Esophageal Motility · NA · recruiting
- NCT06724913 — Efficacy and Tolerability of a Specialized Food Products for Dietary Therapeutic and Preventive Nutrition Based on Ice C · NA · active not recruiting
- NCT05543811 — The Influence of Food for Special Dietary Use - Spread Enriched With 5-hydroxytryptophan, Theanine and Gamma-aminobutyri · NA · completed
- NCT05490862 — Inflammatory Status of Monocytes in Obesity · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05224037 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Federal State Budgetary Scientific Institution "Federal Research Centre of Nutrition, Biotechnology
- Last refreshed: 11 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05224037.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing